Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varicella zoster virus hyperimmune globulin
- Development stage
- Preclinical
- Lead developer
- Aegros
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Varicella zoster virus hyperimmune globulin (VZV IG) is a plasma-derived hyperimmune globulin being developed by Aegros for the prevention of chickenpox (varicella) and shingles (herpes zoster) in high-risk individuals, such as newborns, pregnant women, and immunocompromised patients. It is manufactured using Aegros's proprietary Haemafrac® technology, an electrodialysis-based plasma fractionation process that isolates and concentrates high-titer, virus-specific polyclonal antibodies from donor plasma. VZV IG provides immediate passive immunity by binding to and neutralizing the varicella-zoster virus (VZV), thereby preventing viral entry into host cells and reducing the risk or severity of infection following exposure.
- Other names
- VZV IGvaricella zoster immune globulinvaricella zoster virus immune globulinvaricella-zoster immune globulinvaricella-zoster virus hyperimmune globulinzoster immune globulinzoster immunoglobulin
02
Targets
NeuraminidaseFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on varicella zoster virus hyperimmune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varicella zoster virus hyperimmune globulin.